浩欧博(688656) - 2021 Q1 - 季度财报

Financial Performance - Operating revenue reached CNY 60,990,393.72, a 199.47% increase year-on-year[8] - Net profit attributable to shareholders was CNY 13,336,533.53, compared to a loss of CNY 5,333,030.55 in the same period last year[8] - Basic earnings per share improved to CNY 0.23 from a loss of CNY -0.11 in the same period last year[8] - Operating profit for Q1 2021 was ¥14,534,958.39, compared to a loss of ¥6,588,367.89 in Q1 2020, indicating a turnaround in profitability[30] - Net profit for Q1 2021 was ¥13,336,533.53, recovering from a net loss of ¥5,333,030.55 in Q1 2020[31] - The company achieved an investment income of ¥2,567,085.16 in Q1 2021, contributing positively to overall profitability[30] - In Q1 2021, the company reported a total comprehensive income of CNY 13,744,318.41, compared to a loss of CNY 556,761.11 in Q1 2020[34] Asset Growth - Total assets increased by 164.21% to CNY 783,139,544.11 compared to the end of the previous year[8] - As of March 31, 2021, total assets reached ¥783,139,544.11, a significant increase from ¥296,410,327.69 on December 31, 2020, reflecting a growth of approximately 164%[22] - Total current assets amounted to ¥608,679,217.30, compared to ¥158,654,487.72 at the end of 2020, indicating a growth of about 284%[22] - The company's total liabilities decreased to ¥66,949,934.56 from ¥90,023,007.92, representing a reduction of approximately 26%[23] - The total equity attributable to shareholders increased to ¥716,189,609.55 from ¥206,387,319.77, marking a growth of around 248%[24] - The total assets of the company amounted to ¥752,820,621.65 in Q1 2021, compared to ¥260,183,218.03 in Q4 2020, indicating substantial growth in asset base[28] Cash Flow and Financing - The net cash flow from operating activities was CNY 7,445,872.43, a significant recovery from a negative cash flow of CNY -10,450,769.74 in the previous year[8] - The company reported a cash inflow from financing activities of ¥479.47 million, a dramatic increase of 24,645.27% due to IPO fundraising[16] - The company raised CNY 518,890,428.41 from financing activities in Q1 2021, a substantial increase from CNY 20,000,000.00 in Q1 2020[37] - The net cash flow from financing activities was CNY 479,469,346.49 in Q1 2021, compared to CNY 1,937,620.40 in Q1 2020, showing a notable increase[37] - The ending cash and cash equivalents balance for Q1 2021 was CNY 506,416,822.95, a significant increase from CNY 77,883,684.47 in Q1 2020[37] Shareholder Information - The total number of shareholders reached 2,828 by the end of the reporting period[12] - The largest shareholder, Hai Rui Xiang Tian Biological Technology (Group) Co., Ltd., holds 55.66% of the shares[12] Research and Development - R&D expenditure as a percentage of operating revenue decreased to 10.67% from 26.78%[8] - Research and development expenses rose to ¥6.51 million, an increase of 19.35% from ¥5.45 million in the previous year, indicating ongoing investment in innovation[16] - Research and development expenses for Q1 2021 were ¥6,508,135.29, up from ¥5,453,130.12 in Q1 2020, highlighting continued investment in innovation[30] Liabilities and Debt Management - Long-term borrowings decreased by 84.53% to ¥3.71 million from ¥23.98 million, attributed to the replacement of loans with IPO funds[15] - The company’s total liabilities decreased to ¥36,859,018.34 in Q1 2021 from ¥54,431,689.38 in Q4 2020, reflecting improved financial health[28] - Total liabilities rose from CNY 90,023,007.92 to CNY 98,235,445.21, with current liabilities totaling CNY 63,227,410.59[43] - The company has a long-term loan of CNY 23,982,978.81, indicating a stable debt structure[43] Inventory and Receivables - Accounts receivable stood at ¥25,391,222.85, down from ¥29,898,529.29, showing a decrease of about 15%[22] - Inventory levels were reported at ¥60,631,082.80, slightly down from ¥61,947,687.01, indicating a decrease of approximately 2%[22] - Other receivables increased by 578.63% to ¥8.42 million, primarily due to interest accrual on idle fundraising deposits[15] Market and Product Development - The company did not report any new products or technologies in this quarter[49] - There were no updates on market expansion or mergers and acquisitions during the call[49]